Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
234.13
+12.17 (5.48%)
At close: Dec 5, 2025, 4:00 PM EST
235.00
+0.87 (0.37%)
After-hours: Dec 5, 2025, 7:58 PM EST
Krystal Biotech Revenue
Krystal Biotech had revenue of $97.80M in the quarter ending September 30, 2025, with 16.65% growth. This brings the company's revenue in the last twelve months to $373.16M, up 54.51% year-over-year. In the year 2024, Krystal Biotech had annual revenue of $290.52M with 473.02% growth.
Revenue (ttm)
$373.16M
Revenue Growth
+54.51%
P/S Ratio
18.11
Revenue / Employee
$1,356,960
Employees
275
Market Cap
6.79B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
KRYS News
- 10 days ago - Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 20 days ago - Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth - Seeking Alpha
- 4 weeks ago - Krystal's Q3: Platform Designation Adds Pipeline Leverage As Vyjuvek Scales (Rating Upgrade) - Seeking Alpha
- 4 weeks ago - Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin - Benzinga
- 2 months ago - Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label - GlobeNewsWire
- 3 months ago - Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting Update - Seeking Alpha
- 3 months ago - Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer - GlobeNewsWire